The pros and the cons of mTOR inhibitors in kidney transplantation

Claudio Ponticelli

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Sirolimus and its derivate everolimus are two immunosuppressive drugs with similar chemical structure that inhibit the proliferation of T cells by interfering with a serine-threonine kinase, called mTOR. Apart from their immunosuppressive effects, these agents may also inhibit endothelial intimal proliferation, the replication of cytomegalovirus, and the development of certain cancers. The main dose-dependent adverse events of mTOR inhibitors are hyperlipidemia, thrombocytopenia, mucositis, edema, and proteinuria. The use of mTOR inhibitors in renal transplantation may allow to reduce the doses of calcineurin inhibitors. Withdrawal of calcineurin inhibitors is also possible and may improve renal function, but some patients do not tolerate this regimen because of side effects. Further studies are needed to assess the role of mTOR inhibitors in the long-term.

Original languageEnglish
Pages (from-to)295-305
Number of pages11
JournalExpert Review of Clinical Immunology
Volume10
Issue number2
DOIs
Publication statusPublished - Feb 2014

Fingerprint

Immunosuppressive Agents
Kidney Transplantation
TOR Serine-Threonine Kinases
Tunica Intima
Mucositis
Sirolimus
Hyperlipidemias
Cytomegalovirus
Proteinuria
Thrombocytopenia
Edema
T-Lymphocytes
Kidney
Pharmaceutical Preparations
Neoplasms
Calcineurin Inhibitors
Everolimus

Keywords

  • everolimus
  • kidney transplantation
  • mTOR
  • proliferation signal inhibitor
  • rejection
  • sirolimus

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

The pros and the cons of mTOR inhibitors in kidney transplantation. / Ponticelli, Claudio.

In: Expert Review of Clinical Immunology, Vol. 10, No. 2, 02.2014, p. 295-305.

Research output: Contribution to journalArticle

@article{47157122f5784e7b8dcc5b3b77338c43,
title = "The pros and the cons of mTOR inhibitors in kidney transplantation",
abstract = "Sirolimus and its derivate everolimus are two immunosuppressive drugs with similar chemical structure that inhibit the proliferation of T cells by interfering with a serine-threonine kinase, called mTOR. Apart from their immunosuppressive effects, these agents may also inhibit endothelial intimal proliferation, the replication of cytomegalovirus, and the development of certain cancers. The main dose-dependent adverse events of mTOR inhibitors are hyperlipidemia, thrombocytopenia, mucositis, edema, and proteinuria. The use of mTOR inhibitors in renal transplantation may allow to reduce the doses of calcineurin inhibitors. Withdrawal of calcineurin inhibitors is also possible and may improve renal function, but some patients do not tolerate this regimen because of side effects. Further studies are needed to assess the role of mTOR inhibitors in the long-term.",
keywords = "everolimus, kidney transplantation, mTOR, proliferation signal inhibitor, rejection, sirolimus",
author = "Claudio Ponticelli",
year = "2014",
month = "2",
doi = "10.1586/1744666X.2014.872562",
language = "English",
volume = "10",
pages = "295--305",
journal = "Expert Review of Clinical Immunology",
issn = "1744-666X",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - The pros and the cons of mTOR inhibitors in kidney transplantation

AU - Ponticelli, Claudio

PY - 2014/2

Y1 - 2014/2

N2 - Sirolimus and its derivate everolimus are two immunosuppressive drugs with similar chemical structure that inhibit the proliferation of T cells by interfering with a serine-threonine kinase, called mTOR. Apart from their immunosuppressive effects, these agents may also inhibit endothelial intimal proliferation, the replication of cytomegalovirus, and the development of certain cancers. The main dose-dependent adverse events of mTOR inhibitors are hyperlipidemia, thrombocytopenia, mucositis, edema, and proteinuria. The use of mTOR inhibitors in renal transplantation may allow to reduce the doses of calcineurin inhibitors. Withdrawal of calcineurin inhibitors is also possible and may improve renal function, but some patients do not tolerate this regimen because of side effects. Further studies are needed to assess the role of mTOR inhibitors in the long-term.

AB - Sirolimus and its derivate everolimus are two immunosuppressive drugs with similar chemical structure that inhibit the proliferation of T cells by interfering with a serine-threonine kinase, called mTOR. Apart from their immunosuppressive effects, these agents may also inhibit endothelial intimal proliferation, the replication of cytomegalovirus, and the development of certain cancers. The main dose-dependent adverse events of mTOR inhibitors are hyperlipidemia, thrombocytopenia, mucositis, edema, and proteinuria. The use of mTOR inhibitors in renal transplantation may allow to reduce the doses of calcineurin inhibitors. Withdrawal of calcineurin inhibitors is also possible and may improve renal function, but some patients do not tolerate this regimen because of side effects. Further studies are needed to assess the role of mTOR inhibitors in the long-term.

KW - everolimus

KW - kidney transplantation

KW - mTOR

KW - proliferation signal inhibitor

KW - rejection

KW - sirolimus

UR - http://www.scopus.com/inward/record.url?scp=84893092734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893092734&partnerID=8YFLogxK

U2 - 10.1586/1744666X.2014.872562

DO - 10.1586/1744666X.2014.872562

M3 - Article

C2 - 24377908

AN - SCOPUS:84893092734

VL - 10

SP - 295

EP - 305

JO - Expert Review of Clinical Immunology

JF - Expert Review of Clinical Immunology

SN - 1744-666X

IS - 2

ER -